Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This fact, and this fact alone, should be something that makes people wonder, not to mention should absolutely have been in the filings.
Not just being paid $100,000 by largest shareholder Wescor for closing merger, the person in charge of merger deal from company side, David Ludvigson, was also CEO of this competitor/partner company, Nanomix. This was not revealed in any of the merger filings. Seems relevant to me and a significant oversight.
Read this and tell me there is no conflict of interest:
the solution for rapid, in-the-field testing likely won’t be Corgenix’s device. It will be a different diagnostic test developed by a California company called Nanomix, which has partnered with Corgenix and Tulane researchers. The Nanomix test is a multiplex device: It can detect multiple diseases at once. This is particularly important in West Africa, where Lassa fever, malaria, and now Ebola are all prevalent. All three of those diseases have similar symptoms—fever, vomiting, diarrhea—but require different treatments. It’s vital for doctors to have a correct diagnosis as early as possible. Nanomix’s device would do just that in minutes.
The Nanomix system is simple and safe. The tested blood is self-contained and easy to dispose. “You take whole blood from a patient and you put the whole blood into an inlet port on the cartridge and then you put that cartridge [and] slide it into the reader,” said David Ludvigson, the CEO of Nanomix. “And then the operator presses the start button. … The cartridge itself contains all of the biology and all of the patient’s sample and the instrument never sees that. It becomes bio disposable.”
Nanomix was focused on cardivascular health testing and suddenly came into the Ebola play only middle of last year.
Yeah, there with you. Alot of shady in this, especially as I remember, the merger agreement closing was predicated on lawsuits having been settled. Clearly, they appear to want to push this forward regardless of shareholders. That all said, if they want to pay the $.27 now while this works through courts fine by me.
I have, I believe DB has well. Would definetly like someone to shed more light on things. Crapshoot with SEC though whether they deal with smaller deals like this.
I just think at the very least there are additional questions company should be answering. SEC should be doing more to look at this. First and foremost, why the person from the company most centrally involved in the deal, Ludvigson, was not revealed to also be the CEO of a competitor/partner company. Seems extremely relevant.
With Wescor owning such a large percentage though along with BOD, hard to see company doing this themself. One of those scenarios where it's important that regulatory or legal authorities step in to investigate and ask more questions.
Corgenix and Fio Combine Rapid Ebola Test with Automated Analysis and Data Capture to Improve Frontline Care and Case Tracking
Collaboration leverages Bill & Melinda Gates Foundation and Paul G. Allen Family Foundation grants to automate rapid Ebola testing and increase access to reliable data from the field
Corgenix and Fio Combine Rapid Ebola Test with Automated Analysis and Data Capture to Improve Frontline Care and Case Tracking
DENVER & TORONTO--(BUSINESS WIRE)--
Corgenix Medical Corporation (OTC QB: CONX.OB) and Fio Corporation today announced that they are working together to integrate two technological advances to help end the Ebola outbreak in West Africa: a rapid test, backed by the Bill & Melinda Gates Foundation and the Paul G. Allen Family Foundation, that can detect the virus in minutes; and a mobile device, which is being adapted with further funding from the Gates Foundation, to analyze and upload results directly to a central data system.
Fio is adapting its Deki™ Reader to work with the Corgenix ReEBOVTM Antigen Rapid Test for the Ebola virus, which recently received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) and was listed as eligible for procurement by the World Health Organization (WHO). Combining these technologies will give suspected Ebola patients in the most remote, resource-poor settings, access to automated test results. Results will then immediately be transmitted to Fio’s data system, Fionet™, capturing vital information that is currently missed or delayed.
“This collaboration makes testing more accessible to those at risk and data more readily available to those managing the outbreak, a combination that the Gates Foundation identified and mobilized,” said Dr. Michael M. Greenberg, chairman and CEO of Fio. “The resulting technology will expand the capability to fight Ebola now and strengthen national health systems beyond the current crisis.”
Corgenix researchers on the ground in Sierra Leone have already started using smartphones to transmit images of rapid Ebola test results to the Fionet data system. Together with Fio’s tools for case and contact mapping, this capability offers governments and other organizations responding to the outbreak a way to track the disease in real time.
“We’re taking the fight against Ebola to another level with Fio’s data collection and management, which is critical to the success of rapid testing,” said Douglass Simpson, Corgenix president and CEO. “This marks a tremendous advancement in Ebola testing, and it lays the groundwork for a strong and productive partnership between our two companies on future projects.”
The instant traceability of infected or potentially infected individuals – knowing test results, locations and movement over time and across borders – is essential to containing the spread of the Ebola virus and other highly contagious diseases.
Both companies will continue to work together to integrate the two technologies for decentralized Ebola virus testing throughout West Africa. Beyond the current crisis, this will serve health systems more broadly to better manage future outbreaks, as well as other infectious diseases in the region, such as Lassa virus.
. . Related Quotes .
CONX
0.265
Corgenix Medical Corp.? Watchlist 0.265
OTC MarketsMon, Mar 9, 2015 3:17 PM EDT
CORGENIX MEDICAL CORP/CO Financials EDGAR Online Financials 18 days ago
CORGENIX MEDICAL CORP/CO Files SEC form 10-Q, Quarterly Report EDGAR Online 24 days ago
More . Fio’s Deki Reader – which is already CE-marked for use with rapid tests that detect malaria and dengue fever – is also being adapted for use with the Corgenix ReLASV® Antigen Rapid Test for the Lassa virus.
Fio received a Gates Foundation grant in December 2014 to adapt its Deki Reader to analyze rapid Ebola tests and transmit results to Fionet to be integrated with case and contact management tools.
A few weeks later, Corgenix received two grants – one from the Gates Foundation and one from the Paul G. Allen Family Foundation – to advance the company’s development of an Ebola rapid test kit.
Both the ReLASV® Antigen Rapid Test and the ReEBOVTM Antigen Rapid Test have not been cleared for routine diagnostic use by the U.S. Food and Drug Administration.
The ReLASV® Antigen Rapid Test is CE-marked for diagnostic use in EU and other countries that recognize the CE mark.
The ReEBOVTM Antigen Rapid Test is not CE-marked and may only be used as a diagnostic device under the conditions of the Emergency Use Authorization issued by the U.S. Food and Drug Administration.
About Fio Corporation
Operating at the nexus of care delivery and data, Fio is focused on decentralized management of infectious diseases in developed and developing countries alike. Fio helps health workers of all skill levels improve the quality of care they provide to individual patients, while automatically capturing and disseminating data to strengthen health systems as a whole. Fio’s solution combines mobile intelligent devices with cloud information services to facilitate healthcare delivery that drives, rather than competes with, data capture. Fio is headquartered in Toronto, Canada, with commercial operations underway in Latin America, Africa and Europe.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world’s only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).
Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
Corgenix Medical Corp. William Critchfield, 303-453-8903 Senior VP Operations and Finance and CFO wcritchfield@corgenix.com or Armada Medical Marketing for Corgenix Dan Snyders, 303-623-1190 x230 Vice President and Public Relations Supervisor dan@armadamedical.com or Fio Corporation Asher Greenberg, +1 416-309-2706 Project Coordinator and Communications Officer agreenberg@fio.com or Marlee Wasser, +1 416-799-3714 Communications Consultant mwasser@fio.com or The Bill & Melinda Gates Foundation media@gatesfoundation.org
So there are many, many things we could focus on in the Corgenix merger story (EliTech Group, Orgentec, Water Streets, Inverness etc.) that still have not been fully dug into, but I am just going to focus on one main one today. David Ludvigson and his role. For me at least, doing the DD on him, there is no way not to think the company should be answering a few more questions here. It also screams to me questionable BOD oversight at best, and other less friendly things at worst. Certainly provides some legitimacy to shareholder complaints or lawsuits. Who knows, but my assumption based on things not being settled yet on the latest case, is that the lawyers and/or plaintiffs may have gotten wind of more than what were are privy too at the moment. There are a whole lot of overlapping webs here, just a question of putting the pieces together
PIECE #1
Corgenix's code of conduct and ethics document
Why start with conduct and ethics document which most people have seen before? There is nothing particularly different in the language versus other public companies, but I think it's important to keep this language in mind when reading the information in piece #2.
Also important to remember this part when hearing the word "employee":
This Code applies to all directors, officers and employees of the Company. (As used herein, the term “employees means all directors, officers and employees of the Company unless specifically stated otherwise or unless the context clearly indicates otherwise).
Here are a few relevant sections:
The assets of the Company are much more than its portfolio of properties, facilities, equipment, corporate funds and computer systems. They include technologies and concepts, business strategies and plans, as well as information about its business. These assets may not be improperly used and/or used to provide personal benefits for employees. In addition, employees may not provide outside persons with access to assets of the Company for the employee's personal gain or in such a manner as to be detrimental to the Company. Employees should protect the Company’s assets and ensure their efficient and proper use.
Employees should avoid any outside financial interest that might influence their decisions or actions on matters involving the Company or its businesses or property. Such interests include, among other things: (i) a personal or immediate family interest in an enterprise that has business relations with the Company; or (ii) an enterprise or contract with a supplier, service-provider or any other company or entity that engages in business activities with Company, where the employee or a member of the employee's immediate family is a principal or financial beneficiary, other than as an employee.
Transactions With Employees. Enter into any contract or arrangement, or own any interest in or be a director, officer, consultant or attorney in or for an entity which enters into any contract or arrangement (except for the ownership of non-controlling interests in publicly traded entities) with the Company, or any entity in which the Company may serve as a general partner or managing agent, for any transaction in which the Company or any of the above-described entities related to or affiliated with the Company is a participant, except in those situations specifically approved by the Company's Board of Directors pursuant to previously-adopted polices of the Company on those matters.
Employees owe a duty to the Company to advance its legitimate interests when the opportunity arises to do so. Employees should refrain from and shall be prohibited from (i) taking for themselves, or for their personal benefit, opportunities that could advance the interests of the Company or benefit the Company when such opportunities are discovered through the use of Company property; information or position; (ii) using Company property, information or position for personal gain; or (iii) competing with the Company.
Maybe I'm just not seeing it right, but some of what's described below seems to directly contradict this document, particularly the part labeled "Second" below.
PIECE #2
David Ludvigson
Why him? He is a central player in this discussion. Even the company identified him as so in the 8-K filing that postponed the initial merger vote. Now, I have no idea, everything could be above board here certainly and no desire to question Mr. Ludvigson or his role, but I think there are questions here that should be answered. Despite some question surrounding his role and $100,000 payment for closing of deal that some of BOD was not aware of, the BOD decided to continue moving forward.
The new disclosure adds a paragraph to the proxy statement noting that David Ludvigson – who serves on the Corgenix board of directors as the nominee of the company’s largest shareholder, France-based ELITech Group – is slated to be paid $100,000 by ELITech upon closing of Orgentec’s acquisition of Corgenix.
There are multiple avenues we could go down on him, but here is the general background.
First
He was appointed to the BOD in 2010 at an agreement with Elitech Group who made a significant investment into Corgenix, and also got distribution rights from them and a board member in exchange. Ludvigson was that board member. Who was Ludvigson in the Elitech landscape? Well he previously was President/COO of Nanogen, a biotech that went bankrupt and whose assets were then acquired by Elitech. He was then named by Elitech Group to be COO for the American side of company's business. Elitech subsidiary Wescor, Inc. is the American subsidiary who actually holds the shares of the company. So with that deal Ludvigson jumps on the board as EliTech's rep and they own ~45% of the OS.
What this means is just bringing merger vote up to be voted on virtually assured it's passage, especially because Elitech was the one pushing for it. Now why they would want to is a whole other question for another day.
Second
So where the Ludvigson part of the story starts to get both fascinating and murky. In the year after being appointed by the BOD, he becomes Chief Marketing Officer for a company called Nanomix (http://nano.com) and then 2 years after in 2013 he becomes CEO of Nanomix. Why does this matter? Well this company is in the exact same diagnostic field as Corgenix. In fact, Corgenix and Nanomix have been apparently been partnering on Ebola test kit. Look at front page of Nanomix and you'll see what I mean. Yet, besides one quick mention of Ludvigson's role at Nanomix in a 2013 DEF14A, there was no other mention in any filing (10-K etc.). Surprising especially in light of his role with the company and the ethics code set out. Regardless of merger question, as a shareholder I certainly would have wanted to know this information. Definetly relevant to how I view Ludvigson and his role with the company.
Third
But, lest you think the story ends there it does not. When the acquisition/merger comes into play things get even murkier. Basically Ludvigson was put in charge of the company's search for a target company in conjunction with Inverness. Yes, the same person who was put on the board by the largest shareholder Elitech (owns 45%+ of OS), who will be paid $100,000 if the deal closes (some BOD unaware of), and who now is the CEO of a similar company, Nanomix, is the main one put in charge of target search along with Inverness for Corgenix's assets. Unusual, at least from where I stand.
Here is text on his role in negotiations and search for targets:
Following the report from Mr. Ludvigson, the directors agreed that it was appropriate to advance the exploration effort, and appointed a Strategic Subcommittee consisting of Mr. Gouze (Chairman of the Subcommittee) and Mr. Ludvigson to be responsible for interacting with both potential investment bankers and senior management. Mr. Ludvigson was responsible for organizing the planned face-to-face meetings with the candidate firms including scheduling and pre-meeting preparation of detailed agendas including specific questions our board wished to have answered by the candidate firms.
Water Street represented Orgentec who got the agreement
On April 30, 2014, Mr. Ludvigson learned that Water Street was pursuing opportunities in the diagnostics space and suggested that Inverness contact principals at Water Street. Inverness contacted Water Street the following day and set up a conference call with Corgenix senior management for the following week. Corgenix believes Mr. Ludvigson was introduced to Water Street through a personal relationship between Water Street and a member of ELITech’s board of directors.
]Incentive Payment Description
an incentive payment from our largest shareholder to the board member serving as its nominee on our board of directors upon closing of the merger;
David Ludvigson serves on our board of directors as the nominee of our largest shareholder. On February 3, 2014, Mr. Ludvigson and our largest shareholder entered into an amendment of their existing agreement for consulting services related to a number of matters, including his position on our board of directors. This amendment has a term of 12 months unless renewed by the parties. In addition to reducing his retainer from $11,333 per month to $8,333 per month, the amendment added for the first time that Mr. Ludvigson will be paid an incentive based on the largest shareholder’s realization of Corgenix shareholdings upon the closing of a transaction or sale of the largest shareholder’s shares of Corgenix stock. The incentive payment would vary based on the amount realized from $50,000 to $250,000. Based on the terms of the merger, Mr. Ludvigson will be paid $100,000 upon the closing of the merger. Although our other board members only recently became aware of this incentive payment, our board ratified its approval of the Merger Agreement after it was advised of these arrangements.
Based on the terms of the merger, Mr. Ludvigson will be paid $100,000 upon the closing of the merger. Although our other board members only recently became aware of this incentive payment, our board ratified its approval of the Merger Agreement after it was advised of these arrangements.
All of this for me makes me do a double take. Feel like there may be more than meets the eye. The fact that some BOD unaware of payment arrangement is a bit of a red flag, was the full board aware that he was also CEO of Nanomix?
While, there are many questions out of what I've been finding that might help illuminate things more, I'll start with three.
(1) Who were the other target companies interested in bidding? What was Ludvigson's role in that process? Was he involved in the specific discussions or just Inverness? (2) What new companies invested in Nanomix in the latest $12 million round at beginning of 2014? (They currently have $50 million in investment funding overall) (3) Why wasn't the change in Ludvigson's biography adequately communicated to shareholders, in light of companies own polices and widely accepted filing practices of notifying shareholders if there could be a conflict of interest?
On my end, I'm still wrapping my head around the many pieces, and unsure who is benefitting from all of this, but I think at the very least there are alot of questions that shareholders deserve the answers to and hopefully the legal route will open some of them up if the company is not. I am certainly not convinced at all that BOD has been most concerned with acting in the interests of shareholders knowing the information they have known. Would be nice if SEC would peek into to make sure everything is above board here.
one cloudy area from what I've read is it seems they are just asking for votes of people who held on the record date 'last year' and not current holders
Yeah, I think it makes a very attractive target considering it was in the .40's soon before announcing. We'll see. The recent plaintiff issues should give this more time to evolve and develop. And company can't just ram it down shareholders throats.
Definetly one of those few penny plays that screams institutional money potential. I think people buying on that news spike, now selling because they didn't do DD. At some point share supply will be getting much tighter once people figure it all out and as we start to accumulate more of these shares.
it will take people speaking up though.. I read something on yahoo where the judge said something like there really weren't many objections filed by shareholders
to have a chance we need a voice
an activist with a few $mil can make this happen imo
Buy at .26, pretty much guaranteed at least 3.8% return with much, much bigger upside if deal falls through or terms change. Downside risk virtually nil from what I'm seeing. As safe a pick as I've seen in penny land.
Good idea.... More shareholders are filing objections....next hearing is April 30 Th 1:30. Some brokerage firms fail to notify all share holders of the right to file an objection.
Only one of the two lawsuits has been settled from what I see. The other one had the plaintiffs start to play hard ball a few weeks ago, probably in light of recent news. I still think they have great case considering all that's happened.
That said, man I've never seen a BOD so badly mangle a company, value would be $1+ if they hadn't pulled rug. Really makes you wonder why any reasonable person would do that right after stock PPS started surging, or if it wasn't really about reason at all, but rather the connections to the Orgentec.
Regardless, my personal odds are:
85% happens as is 10% pot gets sweetened 5% deal gets pulled
1. Happens as is means essentially 0% return, no significant gain, but no loss 2. Pot gets sweetened, who knows but up. 3. Deal gets pulled sky is the limit for all of us although I'm sure Orgentec would be none too happy.
As previously disclosed, Corgenix Medical Corporation (the “Company”) and Stephen Gouze, Dennis Fusco, David Ludvigson, Brandon J. Price, Douglass T. Simpson, Robert Tutag, Dennis Walczewski, Centennial Medical Holdings, Inc. (the “Buyer”) and Centennial Integrated, Inc. are defendants in the consolidated action pending in the District Court of Washoe County, Nevada related to the Agreement and Plan of Merger dated August 27, 2014. The parties entered into a Memorandum of Understanding on November 19, 2014, which was also previously disclosed. On December 19, 2014, the parties, through their respective counsel, executed a stipulation of settlement (the “Stipulation”) and related documents formalizing an agreement to settle all of the cases. The Stipulation was filed with the District Court, which entered an order preliminarily approving the proposed settlement and scheduling a hearing on February 19, 2015 for consideration of final approval.
Pursuant to the Stipulation and the District Court’s preliminary approval order, the Company is mailing copies of the Stipulation and a notice of proposed settlement to all record holders or beneficial owners of the Company’s common stock at any time during the period from and including March 11, 2014 through and including the effective date of the merger (the “Notice”) . Any objections to the settlement must be filed in writing with the court by no later than February 5, 2015 in accordance with the Notice.
Closing of the Merger
The closing of the merger is expected to occur in the first quarter of calendar year 2015.
As previously disclosed on page 47 of the proxy statement under the heading “Litigation Related to the Merger,” we are aware of two purported class action complaints that have been filed in connection with the merger. One complaint was filed in the Second Judicial District Court of the State of Nevada on September 4, 2014 — Rauenzhan v. Corgenix, et al., No. CV14-01907. An amended complaint was filed in the Rauenzhan lawsuit on October 14, 2014. One complaint was filed in the First Judicial District Court of the State of Nevada on October 14, 2014 — Bradford, et al. v. Corgenix, et al., No. 14TRT000681B. Counsel for the plaintiffs in the Rauenzhan and Bradford actions agreed to consolidate the actions in the Second Judicial District Court, and the consolidated Second Amended Complaint was filed on November 6, 2014. The consolidated complaint names as defendants us, each member of our board of directors, Buyer and Merger Sub. The consolidated complaint generally alleges that the board of directors breached its fiduciary duties and that we, Buyer, the Merger Sub aided and abetted those purported breaches, in connection with the proposed merger. The consolidated complaint challenges the Merger Consideration as inadequate, and makes a variety of other allegations, including the following:
· given the recent trading price of our Common Stock and potential future growth, the value of our Common Stock is greater than the consideration offered to shareholders in the proposed merger;
· the proposed merger is the result of a flawed process marred by conflicts of interest of our board and senior management;
· the “no solicitation” and termination fee provisions of the Merger Agreement preclude us from soliciting, and otherwise restrict our ability to consider, competing offers; and
· our definitive proxy statement, filed on October 21, 2014 with the SEC, omits and/or misrepresents material information.
The plaintiffs in this case seek an order certifying a proposed class of our shareholders, certifying the plaintiffs as the class representatives, granting injunctive relief against the consummation of the merger, or, if the merger is consummated, rescinding the merger and awarding damages, directing the defendants to account for all damages caused by them and all profits or special benefits obtained by them as a result of their alleged breaches of fiduciary duties and an award of costs, expenses and reasonable attorneys’ fees, and accountants’ and experts’ fees.
On November 19, 2014, the Company entered into a Memorandum of Understanding (“MOU”) with the plaintiffs and certain named defendants with respect to the claims asserted in the lawsuit described above. Pursuant to the MOU, the Company has agreed to provide certain amended disclosures to supplement the proxy statement, all of which are set forth below. In addition, as provided in the MOU, the parties contemplate that plaintiffs’ counsel will seek an award of an agreed upon amount of attorneys’ fees and expenses as part of the settlement, which is subject to court approval. The MOU and settlement will not affect the merger consideration to be paid to the Company’s shareholders in connection with the proposed merger.
hmmm and then I see some comments here* than make it look like this is a done deal and/or 'prior' shareholders 'might' be entitled to further compensation
would explain why anyone can buy in <= .27
ie: there is probably no hope... it is probably too late for this deal to fall apart completely
IMO, somebody played this one perfectly and it wasn't the shareholders
I love this stock for the fact there is very limited risk, either the buyout goes through at .27 or if not PPS is much, much higher. As safe and legit a play as you can find in penny land.
I've had my eye on this one for a little while. I follow biotech/biomed quite a bit. Without the pending buyout at $,27 this would probably trading well over $1. Maybe the board will perform their fiduciary duty and blow off the sale.
2/25/15: FDA Approved Emergency Use of Corgenix's Ebola Rapid Test See screenshot below for e-mail proof I received from FDA mailing list, which anyone can join:
The “fiduciary-out” also allows the Company Board of Directors to change its recommendation that shareholders vote in favor of the Merger in case of “intervening events” or material developments lead the Board of Directors to conclude, after consultation with its financial advisor and outside counsel that in light of such intervening event, failure to take such action would reasonably be expected to be inconsistent with its fiduciary duties under applicable law.
Sure seems like a material development to me. Now whether the BOD are true to their word or not remains to be seen. Getting product approved by WHO should change the equation and any valuation that has been done on company.
News: World Health Organization says it has approved rapid Ebola test by US firm Corgenix, if effectively deployed will give test results within 15 minutes - @Reuters
If not for the bad deal of being acquired at a huge discount .27 this stock would be dollars per share on all the Ebola solutions they are providing. CEO needs to be run out of the company along with his shizzy deal.
db7, I think I got the float mixed up with another ticker I'm looking at and its quite a bit higher than 10 mil, but still attractive. If I get in under .27, I get in. If not, oh well. GLTY/GLTA
Welcome to the Corgenix Medical Corp board OTC: CONX. Please visit the company website for more information. http://www.corgenix.com/
CONX is currently trading on the OTCQB Market with all information current and SEC reporting. More information on the OTC Website here. You can find all filings for CONX on the SEC Website here.
Blockbuster News:
Corgenix Rapid Diagnostic Ebola Test Research Earns Divisional Best Abstract Award at AACC 2014 Meeting
CHICAGO — July 30, 2014 — Corgenix Medical Corporation (OTC BB: CONX.OB) has been recognized for outstanding research presented today at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago. Corgenix earned the award for its poster abstract “Development of a Point-of-Care Diagnostic for Ebola and Sudan Virus Detection,” presented at the conference by Corgenix Research Associate Abby Jones, M.S.
Corgenix, Research Group Announce NIH Grant to Advance Work on Ebola Rapid Diagnostic Test Kit
DENVER — June 26, 2014 — Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, has been awarded a three-year, $2.9 million National Institutes of Health (NIH) grant to advance the development of an Ebola rapid diagnostic test kit. Collaborating with Corgenix on the program will be members of the Viral Hemorrhagic Fever Consortium (VHFC), a collaboration of academic and industry members headed by Tulane University and partially funded with support from the NIH.
News 
Market Data 
Discover 
